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Pancreatic Lymph Node-Derived CD4CD25
Treg Cells: Highly Potent Regulators
of Diabetes that Require TRANCE-RANK Signals
although cell-cell contact and the production of antiin-
flammatory cytokines like IL-4, IL-10, and transforming
growth factor  (TGF) have all been implicated as parti-
cipants (Asseman et al., 1999; Homann et al., 1999; Read
et al., 1998; Suri-Payer et al., 1998; Thornton and She-
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ways between antigen presenting cells (APCs) andUniversity of Cambridge
T cells that are required for efficient activation of CD4Cambridge CB2 2XY
T cells (e.g., B7-CD28 and CD40-CD154) are, not surpris-United Kingdom
ingly, required for Treg cell generation, less is known4 Department of Immunology
about other important signals between APCs and CD4University of Pennsylvania
T cells that are specifically required for Treg cell gener-Philadelphia, Pennsylvania 19104
ation.
Inflammation following, e.g., viral infections, has been
linked to the development of several autoimmune dis-
eases, including multiple sclerosis, rheumatic arthritis,
and type 1 diabetes (Ehl et al., 1998), yet the mechanismsSummary
by which inflammation perpetuates autoimmunity are
unknown. One hypothesis is that inflammation promotesInflammation can activate self-reactive CD8 T
maturation of APCs, facilitating crosspresentation ofcells and induce autoimmunity. Here we show in a
host antigen to self-reactive T cells, resulting in T cellCD8 T cell-mediated model of type 1 diabetes that
priming as opposed to their deletion or anergy (GreenCD4CD25 Treg cells prevent  cell destruction fol-
et al., 1998). In this circumstance, CD4 T cells that arelowing localized inflammation in the islets of Langer-
normally required for APC activation are unnecessaryhans. These Treg cells accumulate preferentially in the
(Green et al., 2000).pancreatic lymph nodes and islets but not other lymph
Studies in murine models of type 1 diabetes, e.g., thenodes or spleen. PLN-derived Treg cells are extremely
nonobese diabetic (NOD) mouse, have demonstratedpotent; only 2  103 cells are needed to prevent diabe-
that the islets of Langerhans become rapidly infiltratedtes development, and their capacity to regulate is de-
with immune cells several weeks prior to the onset ofpendent on TNF-related activation induced cytokine-
diabetes. This finding led to the hypothesis that autoag-receptor activator of NFB signals. Indeed, blockade
gressive T cells specific for islet antigen are suppressedof this pathway results in decreased frequency of
by regulatory T cells. Diabetes progression may relate,CD4CD25 Treg cells in the PLN, resulting in intra-
therefore, to a subsequent failure in the maintenance ofislet differentiation of CD8 T cells into CTLs and rapid
Treg cell function. However, analysis of regulatory T cellprogression to diabetes.
generation and function in the NOD mouse is severely
restricted due to the fact that not all NOD mice developIntroduction
disease, and animals that do develop disease randomly
over a 6-month period. To study the role of Treg cells
Several mechanisms are believed to contribute to the
in type 1 diabetes, an animal model where diabetes
maintenance of peripheral tolerance of self-reactive development is closely synchronized, has clearly de-
T cells that have escaped negative selection in the thy- fined periods of “regulation” and “aggression,” and ulti-
mus (Heath et al., 1998; Kurts et al., 1998a, 1998b; mately disease development occurs in 100% of the col-
Ohashi et al., 1991; Oldstone et al., 1991). In recent ony within a short time frame is highly desirable.
years, evidence has accumulated demonstrating that a We recently adapted the tetracycline-regulated gene
unique population of CD4 T cells can suppress autoag- transcription system to generate transgenic mice
gressive T cell responses to host antigen both in vitro (termed Tet-TNF mice) where a transcriptional on/off
and in vivo (Read et al., 1998, 2000; Suri-Payer et al., switch could regulate islet-specific expression of TNF
1998; Takahashi et al., 1998, 2000; Thornton and She- (Green and Flavell, 2000). In Tet-TNF mice, expression
vach, 1998, 2000). Although complete definition of the of TNF occurred in the absence of doxycycline (dox)
phenotype of these Treg cells remains to be defined, it and was repressed within 48 hr of supplementing the
is generally accepted that they constitutively express food supply with 2.3 g/kg of dox. By crossing Tet-TNF
the IL-2 receptor chain (CD25) and cytotoxic T lympho- mice to mice that constitutively express the costimula-
cyte-associated antigen-4 (CTLA-4) (Read et al., 2000; tory molecule CD80 on the  cells in the islets of Langer-
Takahashi et al., 2000). The mechanisms by which Treg hans, we showed that in 100% of double-transgenic
cells suppress autoaggressive responses are unknown, Tet-TNF/CD80 mice progression to diabetes could be
prevented, delayed, or accelerated depending on the
duration of TNF expression. In particular, we identified5 Correspondence: richard.flavell@yale.edu
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a unique period between 21–25 days following initiation
of TNF expression at birth where undefined anti-islet
regulatory mechanisms are established that can signifi-
cantly delay diabetes progression. Further, we showed
that these regulatory mechanisms could be overcome
by prolonging TNF expression to 28 or 30 days of age.
Thus, the Tet-TNF/CD80 B6 model for type 1 diabetes
satisfies the important criteria outlined above for the
study of immune regulation of autoaggressive responses
to host antigens.
Here we exploit this model to acquire compelling evi-
dence that contrary to our previous reports CD4 T cells
play a crucial role in the development of diabetes follow-
ing localized inflammation in the islets of Langerhans.
The CD4 T cells, acting as Treg cells, do not inhibit
CD8 T cell recruitment to the islets; instead they sup-
press anti-islet CD8 T cell responses by preventing
intra-islet differentiation of these CD8 T cells into ef-
fector CTL. Through a series of adoptive transfer mod-
els, we further characterize these CD4 Treg cells by
demonstrating that they are CD25, are highly potent
at suppressing anti-islet responses, and specifically lo-
Figure 1. CD4 Treg Cells Regulate Anti-Islet CD8 Cytotoxic T Cellcalize in the pancreas-associated tissues. Furthermore,
Responseswe show that CD4CD25 Treg cell elicitation is depen-
TNF was expressed between 0–25 days in Tet-TNF/CD80 mice.dent on a third signaling pathway: the TNF-related acti-
On days 15, 17, and 19, Tet-TNF/CD80 mice were injected withvation induced cytokine (TRANCE) and receptor activa-
purified anti-CD4 (GK1.5; 0.5 mg/mouse) antibody (squares; n  6),tor of NFB (RANK). Ablation of this pathway results
isotype control Ab (diamonds; n  6), or left untreated (circles;
in decreased frequencies of CD4CD25 Treg cells in n  8). TNF expression was repressed on day 25, and diabetes
pancreas-associated tissue and, as a consequence, progression was monitored by daily measurement glycosuria. Mice
were deemed diabetic if serum glucose levels were 250 mg/dlrapid progression to diabetes.
over a 48 hr period. The data shown are an accumulation of two
individual experiments.Results
CD4 T Cells Delay Progression to Diabetes
tional controls, separate groups of mice were either leftFollowing Localized Inflammation
untreated or injected with anti-CD8 Abs (53-6.7). On dayWe considered two major hypotheses to explain why
25, TNF expression was repressed by placing micerepression of TNF at day 25 delayed progression to
on doxycycline-supplemented food (2.3 g/kg), and thediabetes in Tet-TNF/CD80 mice (Green and Flavell,
progression to diabetes was monitored. All mice either2000). First, since diabetes development in Tet-TNF/
left untreated (n  8) or receiving isotype control AbCD80 mice is CD8 T cell-dependent and CD4 T cell-
(n  6) developed diabetes with delayed kinetics, withindependent, CD8 T cell recruitment and intra-islet
overt disease apparent at 13 weeks of age (Figure 1).expansion could be slowed by repression of TNF. His-
In contrast, mice depleted of CD4 T cells showed rapidtological and FACS analysis determined, however, that
acceleration to diabetes (n  6) within 2 weeks of thethere was no difference in the absolute numbers of CD8
last Ab treatment, with 80% of the mice diabetic by 5T cells present in the islets of Tet-TNF mice in which
weeks of age. Diabetes development resulting from TNF was repressed at day 25 versus mice in which
cell destruction was confirmed by immunohistochemi-TNF was never repressed (data not shown), rendering
cal analysis of the pancreas (data not shown). Micethis hypothesis unlikely. The alternate hypothesis sug-
treated with anti-CD8 Abs were prevented from devel-gests that anti-islet autoaggressive responses are being
oping diabetes as previously reported (Green et al.,actively suppressed. Likely candidate suppressor cells
2000; data not shown), even though CD8 T cell recruit-are the CD4 T cells that dominate islet-infiltrates be-
ment to the islets occurred rapidly after the last Abtween 21–25 days following initiation of TNF at birth
treatment. Therefore, CD8 T cell infiltration resultingin Tet-TNF/CD80 mice. To test this hypothesis, Tet-
from in situ death of CD4 T cells alone is unlikely toTNF/CD80 mice which had been induced to express
be responsible for rapid acceleration to disease in anti-TNF from birth were injected with either anti-CD4 anti-
CD4-treated mice. Instead, CD4 T cells appeared to bebodies (Abs; GK1.5) or isotype control Abs at 15, 17,
required to regulate the anti-islet CD8 T cell response.and 19 days of age to selectively deplete CD4 T cells
during the days 21–25 period when putative regulatory
mechanisms are being formed. Confirmation that this Protection from Diabetes Is Mediated by
PLN-Derived CD4CD25 Treg Cellsanti-CD4 regime prevented CD4 T cell infiltration of
islets between 21–25 days following initiation of TNF Accumulating evidence over the past few years have
clearly documented a critical role for CD4CD25 T cellsexpression was obtained by immunohistochemical anal-
ysis of pancreatic sections (data not shown). As addi- in controlling autoaggressive immune responses. In-
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Table 1. Quantification of CD4CD25 T Cells in Tet-TNF/CD80 Mice
Duration of TNF
% CD4CD25Age of Animal Expression
Peripheral Pancreatic
Spleen Lymph Nodes Lymph Nodes Islets
22 days old never repressed 7%–9% 7%–9% 8%–10% 9%–11%
25 days old never repressed 7%–9% 7%–9% 8%–10% 9%–10%
28 days old never repressed 7%–9% 7%–9% 7%–8% 4%–6%
32 days old never repressed 7%–9% 7%–9% 7%–8% 4%–6%
32 days old repressed at 25 7%–9% 7%–9% 17%–20% 20%–22%
days of age
TNF was expressed from birth to the days shown above. On days 22, 25, 28, and 32, the animals were sacrificed and the percentage of
CD4 T cells that expressed CD25 in the above tissues was examined by FACS.
deed, deficiency in CD4CD25 T cells has been linked diabetes. These findings clearly demonstrate that ex-
tremely potent regulatory T cells are located in theto the development of autoimmune diseases (Salomon
et al., 2000; Shevach, 2000). Thus, we determined CD4CD25 T cell fraction of the PLN.
The extraordinary potency of such few PLN-derivedwhether the duration of TNF expression adversely af-
fected CD4CD25 T cell numbers in Tet-TNF/CD80 CD4CD25 Treg cells to prevent diabetes progression
in our model led to a second series of transfers to ad-mice. TNF expression was initiated at birth, and the
percentage of CD4CD25 T cells in the spleen, periph- dress if CD4CD25 T cells isolated from nonpancreas-
associated tissue also had potent immunoregulatoryeral lymph nodes, pancreatic lymph nodes (PLNs), and
islets was examined by FACS at the time points shown properties. Thus, we isolated CD4CD25 T cells from
either the PLN or a pool of the inguinal, axillary, andin Table 1. At all time points investigated, 7%–9% of
CD4 T cells were CD25 in the spleen and peripheral lateral axillary lymph nodes from Tet-TNF/CD80 donor
mice and monitored the capacity of each fraction tolymph nodes. However, in the PLNs the percentage of
CD4CD25 T cells decreased slightly between days protect against diabetes progression in recipient mice.
As shown in Figure 2B, 2 103 PLN-derived CD4CD2525–32 if TNF was continually expressed in the islets.
Repression of TNF expression at day 25 resulted in a protected Tet-TNF/CD80 mice from developing diabe-
tes as before (n  4) over an 11–12 week observationsubstantial increase in the percentage of CD4CD25
T cells in the PLNs. Similar results were attained upon period. In contrast, non-PLN-derived CD4CD25 T
cells were unable to regulate diabetes protection at thisexamination of the islets where the percentage of
CD4CD25 T cells fell from 9%–10% to 4%–6% be- cell number (n 4), with 100% of recipient mice diabetic
by 21 days post transfer. We tested whether there wastween 25–32 days when TNF was continually ex-
pressed. In contrast, 20%–22% of CD4 T cells were a quantitative or qualitative defect in the capacity of
peripheral lymph node-derived CD4CD25 T cells toCD25 in the islets of mice in which TNF expression
was repressed at day 25 (Table 1). Thus, the duration regulate diabetes. For this, we increased the number of
transferred peripheral lymph node-derived CD4CD25of TNF expression adversely affects the percentage of
CD4CD25 T cells specifically in the PLN and islets. T cells 10-fold. As shown in Figure 2B, even after a 10-
fold increase in number, peripheral lymph node-derivedWe decided to test the physiological significance of
the accumulation of CD4CD25 T cells specifically in CD4CD25 T cells could not delay diabetes progres-
sion (n 4). These data demonstrate that the accumula-the PLN and islets of mice that developed diabetes at
a delayed rate. For this, we designed a series of adoptive tion of highly potent CD4CD25 Treg cells capable of
controlling anti-islet responses occurs in the islets andtransfer models. In all cases, the donor mice were Tet-
TNF/CD80 mice that expressed TNF from 0–25 days, PLN, and this accumulation is adversely affected by
prolonging inflammation in situ.whereas recipient mice expressed TNF from 0–28 days.
In the first series of experiments, we determined whether
PLN-derived CD4CD25 or CD4CD25 T cells (Ste- TRANCE-RANK Signals Form a Major Pathway
for the Generation of Treg Cellsphens and Mason, 2000) had immunoregulatory proper-
ties. CD4 T cells were isolated from the PLN and sorted  cells of the pancreas do not express MHC class II
molecules, suggesting that APCs present in islet infil-into CD4CD25 or CD4CD25 T cell fractions (Figure
2A). Recipient mice were injected with either 2  103 trates may be important for promoting intra-islet Treg
cell generation and activation. The molecular interac-CD4CD25 T cells or 1.4 104 CD4CD25 T cells, and
the progression to diabetes was monitored. As shown in tions that are important for CD4CD25 Treg cell gener-
ation are starting to be unraveled. Both CD28-B7 (Salo-Figure 2A, mice receiving 1.4  104 CD4CD25 T cells
(n  4) progressed to diabetes with slightly delayed mon et al., 2000) and CD40L-CD40 (Kumanogoh et al.,
2001; our unpublished results) interactions betweenkinetics compared to control mice that received no cells
(n  4). However, mice that received only 2  103 CD4T cells and APCs have been shown to be important
for CD4CD25 Treg generation.CD4CD25 T cells were significantly protected from
developing diabetes (n  4). Indeed, even by 120 days Recently, APC activation has been shown to occur
following interaction of a second member of the TNFfollowing transfer only 1/4 of recipients had developed
Immunity
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Figure 3. TRANCE-RANK Signals Are an Integral Component of the
Autoregulatory Pathway
TNF expression was initiated at birth in Tet-TNF/CD80 mice, and
on days 21, 23, and 25 the mice were injected with 100 	g TR-Fc
(squares; n  6), 100 	g isotype control Ab hIgG1 (circles; n  6),
or left untreated (diamonds; n  6). On day 25, TNF expression
was repressed and the progression to diabetes was monitored as
before. The data are representative of two independent experi-
ments.
test whether APC-Treg cell generation was dependent
on TRANCE-RANK signals. TNF expression was in-
duced at birth in Tet-TNF/CD80 mice, and on days
21, 23, and 25 the mice were injected with a TRANCE
receptor-human IgG1 (hIgG1) fusion protein (TR-Fc) that
has been shown to block TRANCE-RANK signals (Bach-
mann et al., 1999). As controls, two separate groups of
mice were either injected with isotype control hIgG1 AbFigure 2. PLN-Derived CD4CD25 T Cells Protect against Diabe-
or left untreated. TNF was repressed on day 25 in alltes in Tet-TNF/CD80 Mice
groups, and progression to diabetes was monitored.(A) Donor Tet-TNF/CD80 mice were induced to express TNF from
Both groups of untreated (n  6) and control Ab-treated0–25 days. On day 30, the PLNs were extracted and isolated lympho-
cytes were incubated with anti-CD4 and anti-CD25 Abs. The (n  6) mice developed diabetes with similar delayed
CD4CD25 and CD4CD25 fractions were collected using a FAC- kinetics, suggesting that the control Ab alone had no
Starplus instrument. Recipient Tet-TNF/CD80 mice were induced to effect on the development of diabetes (Figure 3). To our
express TNF from 0–28 days and on day 32 were injected with surprise, blocking TRANCE-RANK interactions in Tet-
either 2  103 CD4CD25 T cells (circles; n  4), 1.4  104
TNF/CD80 mice exacerbated diabetes progressionCD4CD25 T cells (squares; n 4), or received no cells (diamonds;
(n 6). Indeed, the kinetics of disease progression weren  4). In all cases, the progression to diabetes was monitored as
before. The data represent two independent experiments. similar to that observed for CD4-depleted and CD154-
(B) PLN or pooled peripheral lymph nodes (inguinal, axillary, and deficient Tet-TNF/CD80 mice (Figure 1; our unpub-
lateral axillary) were extracted from donor mice described above. lished observations). This result was unexpected, since
The CD4CD25 fraction was collected using a FACStarplus machine previous studies have demonstrated that in CD154-suf-
as before, and 2  103 PLN (open triangles; n  4) 2  103 non-
ficient mice blocking TRANCE-RANK signals had no ef-PLN-derived CD4CD25 T cells (closed diamonds; n  4), or 2 
fect in the generation of cell-mediated or humoral re-104 non-PLN-derived CD4CD25 T cells (open squares; n 4) were
injected into recipient 30-day-old Tet-TNF/CD80 mice that had sponses to viral infection (Bachmann et al., 1999). Thus,
been induced to express TNF from 0–28 days. The progression to the TRANCE-RANK signal is a third major pathway re-
diabetes was monitored as before. quired for the generation of regulatory mechanisms that
control anti-islet T cell responses.
family, TRANCE (now designated TNFS11; Kwon et al.,
1999), on activated T cells with its receptor, RANK (des- TRANCE-RANK Blockade Results in Decreased
CD4CD25 Treg Cells in Pancreas-ignated TNFSR11A; Kwon et al., 1999), on APCs.
TRANCE and RANK share sequence, structural, and Associated Tissue
We decided to investigate the mechanisms by whichfunctional homology with their CD154 and CD40 coun-
terparts (Anderson et al., 1997). Thus, we decided to blockade of TRANCE-RANK signals promoted autoim-
Regulatory Mechanisms Require TRANCE-RANK Signals
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Figure 4. Disrupting TRANCE-RANK Signals Decreases CD4CD25 T Cell Numbers in Pancreas-Associated Tissue
(A) Tet-TNF/CD80 mice were treated as above, and 1 week following repression of TNF the ratio of CD4:CD8 cells in the CD45 fraction
was determined by FACS analysis. The data are representative of six independent mice examined.
(B) The spleen, peripheral lymph nodes (axillary, lateral axillary, and inguinal), and PLN were extracted from TR-Fc-treated or control hIgG1-
treated Tet-TNF/CD80 mice that were induced to express TNF from 0–25 days. The lymphocytes were gated on CD4 cells, and the
proportion of CD25CD45RBlo cells (arrows) was determined by FACS analysis. Islet-infiltrating cells were isolated following collagenase
digestion of pancreata (Green et al., 1998), and the proportion of CD4CD25 cells (arrows) in a CD45 gate was determined by FACS analysis.
The data are representative of five individual mice examined.
munity in Tet-TNF/CD80 mice. Since TRANCE is prefer- One week following the last TR-Fc or control Ab injec-
tion, FACS analysis demonstrated that there were noentially expressed on CD4 T cells (Josien et al., 1999),
it was possible that TR-Fc-treatment simply promoted detectable differences in the percentage of CD4CD25
CD45RBlo T cells present in either the spleens or periph-CD4 T cell depletion. However, we found no significant
differences in absolute numbers of total CD4 or CD8 eral lymph nodes of TR-Fc or control Ab-treated mice
(Figure 4B). In contrast, there were significant differ-T cells in lymphoid-associated tissues or the pancreas
(data not shown). In addition, FACS analysis of T lym- ences in the percentage of CD4CD25CD45RBlo T cells
present in the islets or the PLNs between control hIgG1-phocyte populations in the thymus, spleen, pooled axil-
lary, lateral axillary, and inguinal lymph nodes or islets treated mice versus TR-Fc-treated mice. Whereas 22%
of the PLNs CD4 T cell pool in control hIgG1-treateddid not reveal significant differences in the percentage
of CD4 or CD8 T cells between TR-Fc and control mice were CD25CD45RBlo, in TR-Fc-treated mice this
number was reduced to 7%. We also performed byAb-treated mice (Figure 4A).
Since the number of total CD4 T cells did not signifi- FACS a detailed examination of CD4CD25Treg cells
in the islets of TR-Fc or control hIgG-treated mice. Tocantly differ between TR-Fc and control Ab-treated
mice, we investigated whether blockade of TRANCE- avoid inaccuracies in the analysis, we gated out nonhe-
matopoietic cells based on expression of CD45. Al-RANK prevented accumulation of Treg cells. For classifi-
cation of Treg cells in the PLN and peripheral lymph though total CD4 T cell numbers were similar for both
groups of mice, there were substantial differences innodes, we used CD4CD25CD45RBlo, well-defined
markers of peripheral Treg cells (Read et al., 2000). For the percentage of CD4CD25T cells (Figure 4B, bottom
panel). Whereas 23% of islet-infiltrating hematopoieticislet Treg cell analysis, we measured CD4CD25 Treg
cell numbers located within a CD45 gate. Tet-TNF/ cells were CD4CD25 T cells in control Ab-treated
mice, this number was reduced to 1% for TR-Fc-treatedCD80 mice were induced to express TNF from 0–25
days and injected with either TR-Fc or hIgG1 as before. mice.
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TRANCE-RANK Signals Prevent Intra-Islet
Differentiation of Islet-Reactive CD8
T Cells into Cytotoxic Effectors
Our above-mentioned findings clearly demonstrated the
importance of the CD4CD25 Treg cells in preventing
diabetes progression in Tet-TNF/CD80 mice. We there-
fore decided to determine the mechanism(s) by which
these CD4CD25 Treg cells control anti-islet CD8
T cells’ responses. Since insulitis is a prerequisite for
the development of diabetes (Delovitch and Singh, 1997;
Green and Flavell, 2000), we tested whether transfer of
regulatory CD4CD25 T cells prevented diabetes by
modulating insulitis. To do this, we performed histologi-
cal studies to determine whether islet infiltration is pres-
ent in Tet-TNF/CD80 recipient mice that received 2 
103 PLN-derived CD4CD25 T cells. As shown in Figure
6A, transfer of PLN-derived CD4CD25 T cells does
not prevent or result in the loss of islet infiltrates. Further-
more, there were no distinct differences in the types of
cells recruited to the islets in these mice in comparison
Figure 5. TRANCE-RANK Blockade Prevents CD4 T Cells from De- to diabetic Tet-TNF/CD80 mice that did not receive
laying Diabetes Progression
Treg cells (data not shown). In particular, CD8 T cells
PLN-derived CD4T cells were isolated from TR-Fc-treated or con-
were readily detectable; thus, CD4CD25 Treg cellstrol hIgG1-Ab treated mice that expressed TNF from 0–25 days, 1
do not prevent recruitment of potential autoaggressiveweek after the last Ab treatment. Thirty-day-old Tet-TNF/CD80
CD8 T cells to the islets (data not shown).mice that expressed TNF from 0–28 days of age received 2  104
CD4 T cells from either TR-Fc-treated donors (diamonds; n  4), An alternative explanation was that Treg cells prevent
hIgG Ab-treated donors (circles; n  4), or saline (squares; n  4). intra-islet differentiation of autoaggressive CD8 T cells
In all cases, progression to diabetes was monitored as before. The into cytotoxic effectors (CTLs) capable of destroying 
data are an accumulation of two independent experiments.
cells. We decided to test this hypothesis by reexamining
the Tet-TNF/CD80 mice that had been treated with
either TR-Fc or control hIgG1 Abs, since our data clearlyTo determine further the importance of this low per-
established that rapid disease progression in these for-centage of CD4CD25CD45RBlo T cells in the PLNs of
mer mice relates to a loss in CD4CD25Treg cell elicita-TR-Fc-treated mice in the progression to diabetes, we
tion. Tet-TNF/CD80 mice were induced to expresstransferred total PLN-derived CD4 T cells from TR-
TNF from 0–25 days of age, and on days 21, 23, andFc or hIgG1-treated mice into recipient Tet-TNF/CD80
25 the mice were injected with 100	g of TR-Fc or controlmice and monitored diabetes progression. As a control,
hIgG1 Abs as before. On day 32, the mice were sacrificeda separate group of recipients received saline. Injection
and the number of intra-islet CTL was measured in situof saline into recipient mice resulted in overt diabetes
by staining for perforin, a CTL-specific gene product.which was apparent 15 days following injection, kinetics
As shown in Figure 6B, in control hIgG1-treated micethat would be obtained without any treatment (Figure
few perforin-positive CD8 T cells were detectable 15). Similar kinetics and penetrance of diabetes were also
week after the last Ab treatment. In contrast, in TR-seen in recipient mice that received CD4 T cells from
Fc-treated mice there was a substantial proportion ofTR-Fc-treated donors, suggesting Treg cells were either
perforin-positive CD8 T cells present in the islets. Thus,absent or defective in these donor mice. The similar
reduced numbers of CD4CD25CD45RBlo cells in thekinetics for disease progression in mice receiving saline
PLN and CD4CD25 T cells in the islets of TR-Fc-or CD4 T cells from TR-Fc-treated donors argues
treated mice led to enhanced differentiation of islet-against the possibility that TR-Fc treatment causes the
infiltrating CD8 T cells into CTL effectors. Further, sincegeneration of autoaggressive CD4 T cells. In contrast,
control hIgG Ab treatment has no impact on the abilitytransfer of CD4 T cells from control hIgG1 Ab-treated
of CD4CD25 T cells to delay diabetes progressionmice significantly delayed progression to diabetes in
(Figure 5), the data suggest that CD4CD25 T cellsrecipient mice, with overt disease only apparent 43 days
which accumulate in the PLN and islets of Tet-TNF/following transfer. Further, TR-Fc-treatment of Tet-
CD80 mice delay diabetes by preventing intra-islet dif-TNF/CD80 mice on days 32, 34, and 36 did not acceler-
ferentiation of CD8 T cells into CTL.ate diabetes progression, suggesting Treg cell function
was not impaired once Treg cells have been recruited
to the PLN and islets (data not shown). In addition, in Discussion
vitro studies have demonstrated that TR-Fc is unable
to block CD4CD25Treg cell suppressor function (data Efficient priming of CD4 T cells results from the interac-
tion of mature APCs bearing peptide-MHC class II com-not shown). These data provide compelling evidence
that blockade of TRANCE-RANK signals during a unique plexes. It is well established that APC maturation results
from interaction of CD154 on CD4 T cells and CD4021–25 day period is sufficient to abrogate anti-islet CD4
autoregulatory mechanisms, potentially by preventing on APCs, and such signals result in the upregulation of
MHC-peptide complexes and costimulatory moleculesaccumulation of CD4CD25 T cells in the target organ.
Regulatory Mechanisms Require TRANCE-RANK Signals
189
Figure 6. CD4CD25 Treg Cells Prevent In-
tra-Islet Differentiation of CD8 T Cells to Ef-
fector CTL
(A) The pancreata was isolated from nondia-
betic recipient Tet-TNF/CD80 mice 120 days
after receiving PLN-derived CD4CD25
T cells. Islet-infiltrating cells were detected
by hematoxylin and eosin staining of paraffin-
embedded 5–7 	m sections.
(B) The pancreata were isolated from the do-
nor mice described above. Frozen sections
(5–7 	M) were stained with anti-CD8 (brown)
and anti-perforin (purple) Abs. A representa-
tive example of a perforin-positive CD8
T cell is indicated by an arrow. The data are
representative of four individual mice ana-
lyzed.
on the APC, as well as expression of survival factors neous model for autoimmune diabetes (Salomon et al.,
2000). However, our evidence that transfer of only 2 like Bcl-XL (Banchereau and Steinman, 1998). Several
reports have shown that APC activation can also result 103 CD4CD25T cells was sufficient to completely pro-
tect against diabetes development is unprecedented.under inflammatory conditions in the absence of CD154-
CD40 signals, and such APCs are efficient activators of Indeed, previous reports have documented that ranges
of 1.5  105–5  106 Treg cells are normally required toCD8 T cells and, to a lesser extent, CD4 T cells (Green
et al., 2000; Oxenius et al., 1996; Whitmire et al., 1996). suppress various autoimmune diseases, including dia-
betes (Fowell and Mason, 1993; Gershon and Kondo,Thus, in inflammation-based models of autoimmunity
CD4 T cell help for APC and CD8 T cell activation is 1970).
It is interesting that increase in these putativenot required, leading to the speculation that CD4T cells
have no role to play in disease progression (Green et CD4CD25 Treg cells occurs in the islets or the islet-
draining PLN but not the spleen nor non-PLN (e.g., axil-al., 2000; Herrera et al., 1994). Our results argue strongly
against this hypothesis. Indeed, through the use of a lary) lymph nodes. This site-specific accumulation of
Treg cells in the PLN and islets may be the result ofunique model for inflammation-mediated autoimmunity,
we have defined an hitherto unknown role for CD4 localized production of chemokines that specifically re-
cruit Treg cells to the site of inflammation. Alternatively,T cells in regulating autoimmunity following a localized
inflammatory response. These CD4 T cells are not re- it is possible that Treg cells are antigen specific and
require specialized APCs for their activation or genera-quired for the generation of autoimmunity; instead, they
act as regulatory T cells that act to suppress the anti- tion of their effector function. Although several studies
have attempted to determine whether Treg cells areislet CD8T cell response by preventing intra-islet differ-
entiation of CD8 T cells into CTL effectors. antigen specific, the data obtained have yet to yield
conclusive evidence of Treg cell antigen specificity (re-We have established that these Treg cells are con-
tained within the CD4CD25 T cell fraction that viewed in Shevach, 2000). Certainly our data clearly
demonstrate that the islet and PLN are unique in theiraccumulates in the PLNs and islets following repres-
sion of the inflammatory response. This was first sug- capacity to propagate functional Treg cells in our model,
since transfer of much greater numbers of CD4CD25gested by the observations that decreased numbers of
CD4CD25 T cells in these locations correlated with T cells from non-PLN-derived lymph nodes cannot pro-
tect against diabetes development.acceleration to diabetes and was later confirmed in
transfer experiments where PLN-derived CD4CD25 Another important finding is that TRANCE-RANK in-
teractions are critical in promoting regulatory responsesand not CD4CD25T cells prevented diabetes progres-
sion in Tet-TNF/CD80 mice. This finding is consistent that control anti-islet autoaggressive T cells. TRANCE-
RANK interactions have previously been shown to bewith recent reports demonstrating that the failure to
generate CD4CD25 T cells correlates with acceler- important for B and T cell development in primary
lymphoid organs as well as the development of lymphated diabetes progression in the NOD mouse, a sponta-
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were fixed in 10% formalin solution (Sigma) prior to embedding innodes and bone resorption (Kong et al., 1999). In the
paraffin.periphery, TRANCE-RANK interactions can substitute
for ablation of CD154-CD40 signals to promote anti-viral
HistologyT cell responses (Bachmann et al., 1999). However, our For detection of CD8 and perforin, 5–7 	M frozen sections were
data clearly demonstrate that TRANCE-RANK interac- incubated with unconjugated rat anti-CD8 [53-6.7, ATCC] followed
tions are crucial to the development of regulatory re- by an HRP-labeled anti-rat Ab (Southern Biotechnology, Inc., Bir-
mingham, AL) and 3,3
-diaminobenzidine tetrahydrochloride (DAB)sponses in animals where CD154-CD40 signals are in-
substrate kit (Zymed, S. San Francisco, CA). Tissues were thentact. Thus, TRANCE-RANK signals constitute a third
incubated with biotinylated anti-perforin Ab (Kamiya Biochemical,major pathway (along with CD28-B7 and CD154-
Seattle, WA) followed by alkaline phosphatase and BCIP/NBT sub-CD40) that is critical for the generation of regulatory strate kit (Zymed).
CD4CD25 T cell responses. The significance of this
pathway in the development of type 1 diabetes (or other Adoptive Transfers
autoimmune diseases) in animal model in which disease Lymphocytes were isolated from the appropriate tissues, washed
in phosphate-buffered saline supplemented with 2% FBS (PBS/spontaneously develops remains to be defined. In hu-
FBS), and incubated for 15 min with FcR-blocking Abs (2.4G2;man, RANK has been mapped to chromosome 18q22.1,
ATCC) on ice. The cells were washed twice in PBS/FBS, then incu-a genetic location that has recently been linked to the
bated with appropriate fluorochrome-linked Abs. The desired cell
development of both type 1 diabetes and Grave’s dis- populations were subsequently collected using a FACStarplus (Bec-
ease (Merriman et al., 1998; Vaidya et al., 2000). Thus, ton Dickinson, San Jose, CA) instrument. In all cases, the cells
TRANCE-RANK interactions may not only be important were washed twice in 0.9% sodium chloride irrigation, USP (Baxter
Healthcare Corporation, Deerfield, IL) prior to injection into the lat-for protection from type 1 diabetes in man but also may
eral tail vein of recipient mice.be involved in controlling other autoimmune diseases.
Our studies also provide data that support the hypoth-
Acknowledgmentsesis that TRANCE-RANK participates in Treg cell gener-
ation rather than effector function. Thus, while TR-Fc- The authors appreciate the help of M. Altieri and T. Prus for islet
treatment of Tet-TNF/CD80 mice (that expressed TNF preparation, A. Santana and D. Butkus and S.K. Howlett for technical
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Manzo for preparation of this manuscript. This work was supportedgeneration, the same treatment on days 32, 34, and
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and Y.C.). R.A.F. is an Investigator and Y.C. is an Associate Investi-Treg cell function was not impaired by TRANCE block-
gator of the Howard Hughes Medical Institute.
ade once Treg cells have been recruited to the PLN and
islets. In addition, in vitro studies have demonstrated Received April 9, 2001; revised December 10, 2001.
that TR-Fc is unable to block CD4CD25 Treg cell sup-
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